Swedish Orphan Biovitrum Accounts Payable 2019-2024 | BIOVF

Swedish Orphan Biovitrum accounts payable for the quarter ending September 30, 2024 were $0.131B, a 34.38% increase year-over-year.

  • Swedish Orphan Biovitrum accounts payable for 2023 were $0.097B, a 22.17% decline from 2022.
  • Swedish Orphan Biovitrum accounts payable for 2022 were $0.124B, a 90.7% increase from 2021.
  • Swedish Orphan Biovitrum accounts payable for 2021 were $0.065B, a 4.9% increase from 2020.

Swedish Orphan Biovitrum Accounts Payable 2019-2024 | BIOVF

  • Swedish Orphan Biovitrum accounts payable for 2023 were $0.097B, a 22.17% decline from 2022.
  • Swedish Orphan Biovitrum accounts payable for 2022 were $0.124B, a 90.7% increase from 2021.
  • Swedish Orphan Biovitrum accounts payable for 2021 were $0.065B, a 4.9% increase from 2020.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$217.3B
Amgen (AMGN)$160.8B
Gilead Sciences (GILD)$136.6B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$96B
CSL (CSLLY)$78.5B
GSK (GSK)$78.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$35.4B
BioNTech SE (BNTX)$27B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.8B
Illumina (ILMN)$15.3B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$14B
Incyte (INCY)$13.4B
Moderna (MRNA)$12.4B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.8B
Regencell Bioscience Holdings (RGC)$7.6B
Legend Biotech (LEGN)$7.3B